Revitalizing psychiatric therapeutics.

Neuropsychopharmacology
Authors
Keywords
Abstract

Despite high prevalence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuropsychiatric disorders as 'too difficult' a challenge to warrant major investment. Here I describe major obstacles to drug discovery and development including a lack of new molecular targets, shortcomings of current animal models, and the lack of biomarkers for clinical trials. My major focus, however, is on new technologies and scientific approaches to neuropsychiatric disorders that give promise for revitalizing therapeutics and may thus answer industry's concerns.

Year of Publication
2014
Journal
Neuropsychopharmacology
Volume
39
Issue
1
Pages
220-9
Date Published
2014 Jan
ISSN
1740-634X
URL
DOI
10.1038/npp.2013.181
PubMed ID
24317307
PubMed Central ID
PMC3857646
Links